Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00090675
Status:
WITHDRAWN
Last Update Posted:
2013-01-29
First Post:
2004-09-02
Brief Title:
Maintenance ZD1839 IRESSA Following Completion of Front Line Platinum-Based Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase IIIb Randomized Double-Blind Study Comparing Maintenance ZD1839 IRESSA or Placebo Following Completion of Front Line Platinum-Based Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
WITHDRAWN
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No patients randomised
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IMACHerbst
Brief Summary:
In this Phase IIIb randomized double-blind maintenance study 300 subjects with advanced or metastatic Non-Small Cell Lung Cancer NSCLC Stage IIIB T4-pleural effusion and IV who have SD or objective tumor response immediately following the completion of 4-6 cycles of front line platinum-based doublet chemotherapy will be randomized in a double-blind manner to receive either ZD1839 or placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Herbst trial | None | None | None |